nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Fluorouracil—head and neck cancer	0.0372	0.593	CbGbCtD
Trametinib—Ocular toxicity—Fluorouracil—head and neck cancer	0.02	0.0708	CcSEcCtD
Trametinib—Skin toxicity—Docetaxel—head and neck cancer	0.0169	0.06	CcSEcCtD
Trametinib—CYP3A4—Vinblastine—head and neck cancer	0.014	0.223	CbGbCtD
Trametinib—CYP3A4—Docetaxel—head and neck cancer	0.0115	0.184	CbGbCtD
Trametinib—Lymphoedema—Docetaxel—head and neck cancer	0.008	0.0283	CcSEcCtD
Trametinib—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.00679	0.024	CcSEcCtD
Trametinib—Hypomagnesaemia—Hydroxyurea—head and neck cancer	0.00592	0.021	CcSEcCtD
Trametinib—Cardiomyopathy—Fluorouracil—head and neck cancer	0.00529	0.0187	CcSEcCtD
Trametinib—Rash generalised—Docetaxel—head and neck cancer	0.00459	0.0163	CcSEcCtD
Trametinib—Rectal haemorrhage—Vinblastine—head and neck cancer	0.00456	0.0162	CcSEcCtD
Trametinib—Cellulitis—Vinblastine—head and neck cancer	0.00453	0.0161	CcSEcCtD
Trametinib—Prurigo—Docetaxel—head and neck cancer	0.00423	0.015	CcSEcCtD
Trametinib—Creatinine increased—Hydroxyurea—head and neck cancer	0.00395	0.014	CcSEcCtD
Trametinib—Lymphopenia—Docetaxel—head and neck cancer	0.00382	0.0135	CcSEcCtD
Trametinib—Neoplasm—Vinblastine—head and neck cancer	0.00373	0.0132	CcSEcCtD
Trametinib—Mucosal inflammation—Docetaxel—head and neck cancer	0.00353	0.0125	CcSEcCtD
Trametinib—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.00342	0.0121	CcSEcCtD
Trametinib—Neoplasm—Hydroxyurea—head and neck cancer	0.0034	0.012	CcSEcCtD
Trametinib—Polyp—Docetaxel—head and neck cancer	0.00321	0.0114	CcSEcCtD
Trametinib—Cellulitis—Fluorouracil—head and neck cancer	0.00298	0.0105	CcSEcCtD
Trametinib—Renal failure acute—Hydroxyurea—head and neck cancer	0.00296	0.0105	CcSEcCtD
Trametinib—Cyst—Docetaxel—head and neck cancer	0.00292	0.0103	CcSEcCtD
Trametinib—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00256	0.00905	CcSEcCtD
Trametinib—Rash erythematous—Docetaxel—head and neck cancer	0.00255	0.00903	CcSEcCtD
Trametinib—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00246	0.00871	CcSEcCtD
Trametinib—Pancreatitis—Hydroxyurea—head and neck cancer	0.00231	0.00819	CcSEcCtD
Trametinib—Neutropenia—Hydroxyurea—head and neck cancer	0.00221	0.00781	CcSEcCtD
Trametinib—Bone disorder—Docetaxel—head and neck cancer	0.00216	0.00766	CcSEcCtD
Trametinib—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00215	0.00761	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00215	0.00761	CcSEcCtD
Trametinib—Infestation NOS—Hydroxyurea—head and neck cancer	0.0021	0.00745	CcSEcCtD
Trametinib—Infestation—Hydroxyurea—head and neck cancer	0.0021	0.00745	CcSEcCtD
Trametinib—Haemoglobin—Vinblastine—head and neck cancer	0.00208	0.00737	CcSEcCtD
Trametinib—Haemorrhage—Vinblastine—head and neck cancer	0.00207	0.00733	CcSEcCtD
Trametinib—Stomatitis—Hydroxyurea—head and neck cancer	0.00205	0.00726	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00195	0.00692	CcSEcCtD
Trametinib—Haemoglobin—Hydroxyurea—head and neck cancer	0.0019	0.00672	CcSEcCtD
Trametinib—Haemorrhage—Hydroxyurea—head and neck cancer	0.00189	0.00668	CcSEcCtD
Trametinib—Dry skin—Fluorouracil—head and neck cancer	0.0018	0.00638	CcSEcCtD
Trametinib—Neoplasm—Docetaxel—head and neck cancer	0.00177	0.00625	CcSEcCtD
Trametinib—Angiopathy—Hydroxyurea—head and neck cancer	0.00171	0.00607	CcSEcCtD
Trametinib—Chills—Hydroxyurea—head and neck cancer	0.00169	0.006	CcSEcCtD
Trametinib—Anaemia—Vinblastine—head and neck cancer	0.00167	0.0059	CcSEcCtD
Trametinib—Erythema—Hydroxyurea—head and neck cancer	0.00164	0.00582	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00163	0.00577	CcSEcCtD
Trametinib—Leukopenia—Vinblastine—head and neck cancer	0.00161	0.00571	CcSEcCtD
Trametinib—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00156	0.00554	CcSEcCtD
Trametinib—Hypertension—Vinblastine—head and neck cancer	0.00156	0.00551	CcSEcCtD
Trametinib—Anaemia—Hydroxyurea—head and neck cancer	0.00152	0.00538	CcSEcCtD
Trametinib—Infestation—Fluorouracil—head and neck cancer	0.00151	0.00536	CcSEcCtD
Trametinib—Infestation NOS—Fluorouracil—head and neck cancer	0.00151	0.00536	CcSEcCtD
Trametinib—Stomatitis—Fluorouracil—head and neck cancer	0.00148	0.00522	CcSEcCtD
Trametinib—Urinary tract infection—Fluorouracil—head and neck cancer	0.00147	0.00521	CcSEcCtD
Trametinib—Leukopenia—Hydroxyurea—head and neck cancer	0.00147	0.00521	CcSEcCtD
Trametinib—Thrombocytopenia—Vinblastine—head and neck cancer	0.00144	0.0051	CcSEcCtD
Trametinib—Epistaxis—Fluorouracil—head and neck cancer	0.00143	0.00506	CcSEcCtD
Trametinib—Hyponatraemia—Docetaxel—head and neck cancer	0.00142	0.00504	CcSEcCtD
Trametinib—Pain in extremity—Docetaxel—head and neck cancer	0.00142	0.00502	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00139	0.00492	CcSEcCtD
Trametinib—Haemoglobin—Fluorouracil—head and neck cancer	0.00137	0.00484	CcSEcCtD
Trametinib—Haemorrhage—Fluorouracil—head and neck cancer	0.00136	0.00481	CcSEcCtD
Trametinib—Oedema—Hydroxyurea—head and neck cancer	0.00134	0.00475	CcSEcCtD
Trametinib—Infection—Hydroxyurea—head and neck cancer	0.00133	0.00472	CcSEcCtD
Trametinib—Dehydration—Docetaxel—head and neck cancer	0.00132	0.00467	CcSEcCtD
Trametinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00132	0.00466	CcSEcCtD
Trametinib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00131	0.00465	CcSEcCtD
Trametinib—Skin disorder—Hydroxyurea—head and neck cancer	0.0013	0.00461	CcSEcCtD
Trametinib—Dry skin—Docetaxel—head and neck cancer	0.0013	0.0046	CcSEcCtD
Trametinib—Abdominal pain upper—Docetaxel—head and neck cancer	0.00129	0.00459	CcSEcCtD
Trametinib—Decreased appetite—Vinblastine—head and neck cancer	0.00128	0.00453	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00128	0.00452	CcSEcCtD
Trametinib—Constipation—Vinblastine—head and neck cancer	0.00126	0.00445	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00125	0.00443	CcSEcCtD
Trametinib—Arrhythmia—Fluorouracil—head and neck cancer	0.00121	0.0043	CcSEcCtD
Trametinib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.0012	0.00426	CcSEcCtD
Trametinib—Erythema—Fluorouracil—head and neck cancer	0.00118	0.00419	CcSEcCtD
Trametinib—Decreased appetite—Hydroxyurea—head and neck cancer	0.00117	0.00413	CcSEcCtD
Trametinib—Abdominal pain—Vinblastine—head and neck cancer	0.00116	0.00412	CcSEcCtD
Trametinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00116	0.0041	CcSEcCtD
Trametinib—Fatigue—Hydroxyurea—head and neck cancer	0.00116	0.00409	CcSEcCtD
Trametinib—Constipation—Hydroxyurea—head and neck cancer	0.00115	0.00406	CcSEcCtD
Trametinib—Neutropenia—Docetaxel—head and neck cancer	0.00115	0.00406	CcSEcCtD
Trametinib—Vision blurred—Fluorouracil—head and neck cancer	0.00111	0.00395	CcSEcCtD
Trametinib—Anaemia—Fluorouracil—head and neck cancer	0.00109	0.00387	CcSEcCtD
Trametinib—Infestation NOS—Docetaxel—head and neck cancer	0.00109	0.00387	CcSEcCtD
Trametinib—Infestation—Docetaxel—head and neck cancer	0.00109	0.00387	CcSEcCtD
Trametinib—Renal failure—Docetaxel—head and neck cancer	0.00107	0.0038	CcSEcCtD
Trametinib—Stomatitis—Docetaxel—head and neck cancer	0.00106	0.00377	CcSEcCtD
Trametinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.00106	0.00375	CcSEcCtD
Trametinib—Leukopenia—Fluorouracil—head and neck cancer	0.00106	0.00375	CcSEcCtD
Trametinib—Asthenia—Vinblastine—head and neck cancer	0.00106	0.00374	CcSEcCtD
Trametinib—Epistaxis—Docetaxel—head and neck cancer	0.00103	0.00365	CcSEcCtD
Trametinib—Myalgia—Fluorouracil—head and neck cancer	0.00101	0.00357	CcSEcCtD
Trametinib—Diarrhoea—Vinblastine—head and neck cancer	0.00101	0.00356	CcSEcCtD
Trametinib—Haemoglobin—Docetaxel—head and neck cancer	0.000986	0.00349	CcSEcCtD
Trametinib—Haemorrhage—Docetaxel—head and neck cancer	0.000981	0.00347	CcSEcCtD
Trametinib—Dizziness—Vinblastine—head and neck cancer	0.000973	0.00344	CcSEcCtD
Trametinib—Urinary tract disorder—Docetaxel—head and neck cancer	0.000969	0.00343	CcSEcCtD
Trametinib—Oedema peripheral—Docetaxel—head and neck cancer	0.000966	0.00342	CcSEcCtD
Trametinib—Oedema—Fluorouracil—head and neck cancer	0.000965	0.00342	CcSEcCtD
Trametinib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000964	0.00341	CcSEcCtD
Trametinib—Asthenia—Hydroxyurea—head and neck cancer	0.000962	0.00341	CcSEcCtD
Trametinib—Urethral disorder—Docetaxel—head and neck cancer	0.000961	0.0034	CcSEcCtD
Trametinib—Infection—Fluorouracil—head and neck cancer	0.000959	0.0034	CcSEcCtD
Trametinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000947	0.00335	CcSEcCtD
Trametinib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000945	0.00335	CcSEcCtD
Trametinib—Vomiting—Vinblastine—head and neck cancer	0.000935	0.00331	CcSEcCtD
Trametinib—Headache—Vinblastine—head and neck cancer	0.000921	0.00326	CcSEcCtD
Trametinib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000918	0.00325	CcSEcCtD
Trametinib—Eye disorder—Docetaxel—head and neck cancer	0.000917	0.00325	CcSEcCtD
Trametinib—Cardiac disorder—Docetaxel—head and neck cancer	0.00091	0.00322	CcSEcCtD
Trametinib—Angiopathy—Docetaxel—head and neck cancer	0.00089	0.00315	CcSEcCtD
Trametinib—Dizziness—Hydroxyurea—head and neck cancer	0.000887	0.00314	CcSEcCtD
Trametinib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000884	0.00313	CcSEcCtD
Trametinib—Chills—Docetaxel—head and neck cancer	0.00088	0.00312	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00088	0.00311	CcSEcCtD
Trametinib—Arrhythmia—Docetaxel—head and neck cancer	0.000876	0.0031	CcSEcCtD
Trametinib—Nausea—Vinblastine—head and neck cancer	0.000874	0.00309	CcSEcCtD
Trametinib—Insomnia—Fluorouracil—head and neck cancer	0.000873	0.00309	CcSEcCtD
Trametinib—Mental disorder—Docetaxel—head and neck cancer	0.000859	0.00304	CcSEcCtD
Trametinib—Erythema—Docetaxel—head and neck cancer	0.000854	0.00302	CcSEcCtD
Trametinib—Malnutrition—Docetaxel—head and neck cancer	0.000854	0.00302	CcSEcCtD
Trametinib—Vomiting—Hydroxyurea—head and neck cancer	0.000853	0.00302	CcSEcCtD
Trametinib—Rash—Hydroxyurea—head and neck cancer	0.000846	0.00299	CcSEcCtD
Trametinib—Dermatitis—Hydroxyurea—head and neck cancer	0.000845	0.00299	CcSEcCtD
Trametinib—Headache—Hydroxyurea—head and neck cancer	0.00084	0.00298	CcSEcCtD
Trametinib—Decreased appetite—Fluorouracil—head and neck cancer	0.000839	0.00297	CcSEcCtD
Trametinib—Dysgeusia—Docetaxel—head and neck cancer	0.000836	0.00296	CcSEcCtD
Trametinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000834	0.00295	CcSEcCtD
Trametinib—Back pain—Docetaxel—head and neck cancer	0.000826	0.00292	CcSEcCtD
Trametinib—Muscle spasms—Docetaxel—head and neck cancer	0.000821	0.00291	CcSEcCtD
Trametinib—Nausea—Hydroxyurea—head and neck cancer	0.000797	0.00282	CcSEcCtD
Trametinib—Anaemia—Docetaxel—head and neck cancer	0.000789	0.00279	CcSEcCtD
Trametinib—Leukopenia—Docetaxel—head and neck cancer	0.000764	0.00271	CcSEcCtD
Trametinib—Body temperature increased—Fluorouracil—head and neck cancer	0.000763	0.0027	CcSEcCtD
Trametinib—Cough—Docetaxel—head and neck cancer	0.000745	0.00264	CcSEcCtD
Trametinib—Hypertension—Docetaxel—head and neck cancer	0.000737	0.00261	CcSEcCtD
Trametinib—Myalgia—Docetaxel—head and neck cancer	0.000727	0.00257	CcSEcCtD
Trametinib—Arthralgia—Docetaxel—head and neck cancer	0.000727	0.00257	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000722	0.00256	CcSEcCtD
Trametinib—Dry mouth—Docetaxel—head and neck cancer	0.000711	0.00252	CcSEcCtD
Trametinib—Oedema—Docetaxel—head and neck cancer	0.000697	0.00247	CcSEcCtD
Trametinib—Infection—Docetaxel—head and neck cancer	0.000692	0.00245	CcSEcCtD
Trametinib—Nervous system disorder—Docetaxel—head and neck cancer	0.000683	0.00242	CcSEcCtD
Trametinib—Pruritus—Fluorouracil—head and neck cancer	0.000683	0.00242	CcSEcCtD
Trametinib—Thrombocytopenia—Docetaxel—head and neck cancer	0.000682	0.00242	CcSEcCtD
Trametinib—Skin disorder—Docetaxel—head and neck cancer	0.000677	0.0024	CcSEcCtD
Trametinib—Diarrhoea—Fluorouracil—head and neck cancer	0.000661	0.00234	CcSEcCtD
Trametinib—Dizziness—Fluorouracil—head and neck cancer	0.000638	0.00226	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000635	0.00225	CcSEcCtD
Trametinib—Insomnia—Docetaxel—head and neck cancer	0.00063	0.00223	CcSEcCtD
Trametinib—Vomiting—Fluorouracil—head and neck cancer	0.000614	0.00217	CcSEcCtD
Trametinib—Rash—Fluorouracil—head and neck cancer	0.000609	0.00216	CcSEcCtD
Trametinib—Dermatitis—Fluorouracil—head and neck cancer	0.000608	0.00215	CcSEcCtD
Trametinib—Decreased appetite—Docetaxel—head and neck cancer	0.000606	0.00214	CcSEcCtD
Trametinib—Headache—Fluorouracil—head and neck cancer	0.000605	0.00214	CcSEcCtD
Trametinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000602	0.00213	CcSEcCtD
Trametinib—Fatigue—Docetaxel—head and neck cancer	0.000601	0.00213	CcSEcCtD
Trametinib—Constipation—Docetaxel—head and neck cancer	0.000596	0.00211	CcSEcCtD
Trametinib—Nausea—Fluorouracil—head and neck cancer	0.000573	0.00203	CcSEcCtD
Trametinib—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00057	0.00202	CcSEcCtD
Trametinib—Abdominal pain—Docetaxel—head and neck cancer	0.000551	0.00195	CcSEcCtD
Trametinib—Body temperature increased—Docetaxel—head and neck cancer	0.000551	0.00195	CcSEcCtD
Trametinib—Asthenia—Docetaxel—head and neck cancer	0.0005	0.00177	CcSEcCtD
Trametinib—Pruritus—Docetaxel—head and neck cancer	0.000493	0.00175	CcSEcCtD
Trametinib—Diarrhoea—Docetaxel—head and neck cancer	0.000477	0.00169	CcSEcCtD
Trametinib—Dizziness—Docetaxel—head and neck cancer	0.000461	0.00163	CcSEcCtD
Trametinib—Vomiting—Docetaxel—head and neck cancer	0.000443	0.00157	CcSEcCtD
Trametinib—Rash—Docetaxel—head and neck cancer	0.000439	0.00156	CcSEcCtD
Trametinib—Dermatitis—Docetaxel—head and neck cancer	0.000439	0.00155	CcSEcCtD
Trametinib—Headache—Docetaxel—head and neck cancer	0.000437	0.00155	CcSEcCtD
Trametinib—Nausea—Docetaxel—head and neck cancer	0.000414	0.00147	CcSEcCtD
Trametinib—MAP2K1—Signaling by PDGF—PIK3CA—head and neck cancer	0.000164	0.000251	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—HRAS—head and neck cancer	0.000163	0.000249	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—HRAS—head and neck cancer	0.000162	0.000248	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—PTEN—head and neck cancer	0.000162	0.000248	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—AKT1—head and neck cancer	0.000162	0.000247	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NOTCH1—head and neck cancer	0.000162	0.000247	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000161	0.000246	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—BCL2L1—head and neck cancer	0.000159	0.000243	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	0.000159	0.000243	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—AKT1—head and neck cancer	0.000159	0.000243	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—PIK3CA—head and neck cancer	0.000159	0.000242	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—AKT1—head and neck cancer	0.000158	0.000242	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	0.000158	0.000241	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—STAT3—head and neck cancer	0.000158	0.000241	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—AKT1—head and neck cancer	0.000157	0.00024	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—AKT1—head and neck cancer	0.000157	0.00024	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	0.000157	0.00024	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—HRAS—head and neck cancer	0.000157	0.00024	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—AKT1—head and neck cancer	0.000157	0.000239	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—AKT1—head and neck cancer	0.000156	0.000238	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	0.000155	0.000237	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—HRAS—head and neck cancer	0.000155	0.000237	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—HRAS—head and neck cancer	0.000155	0.000237	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—STAT3—head and neck cancer	0.000155	0.000237	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—AKT1—head and neck cancer	0.000155	0.000237	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—HRAS—head and neck cancer	0.000154	0.000235	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000154	0.000235	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—AKT1—head and neck cancer	0.000153	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	0.000153	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—HRAS—head and neck cancer	0.000153	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—HRAS—head and neck cancer	0.000152	0.000232	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—MAPK3—head and neck cancer	0.000151	0.00023	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	0.000149	0.000227	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—AKT1—head and neck cancer	0.000149	0.000227	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GRP—head and neck cancer	0.000148	0.000227	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—MAPK3—head and neck cancer	0.000148	0.000226	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—AKT1—head and neck cancer	0.000148	0.000226	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—STAT3—head and neck cancer	0.000147	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	0.000147	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—AKT1—head and neck cancer	0.000147	0.000225	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	0.000147	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—HRAS—head and neck cancer	0.000147	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—AKT1—head and neck cancer	0.000147	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	0.000147	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—AKT1—head and neck cancer	0.000147	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—AKT1—head and neck cancer	0.000146	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—AKT1—head and neck cancer	0.000146	0.000223	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—AKT1—head and neck cancer	0.000145	0.000222	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—STAT3—head and neck cancer	0.000145	0.000221	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT6—head and neck cancer	0.000144	0.00022	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—AKT1—head and neck cancer	0.000144	0.00022	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000144	0.000219	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—AKT1—head and neck cancer	0.000143	0.000219	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—MAPK1—head and neck cancer	0.000143	0.000219	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—AKT1—head and neck cancer	0.000143	0.000218	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000142	0.000217	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—VEGFA—head and neck cancer	0.000142	0.000216	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—MAPK3—head and neck cancer	0.000141	0.000215	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—MAPK1—head and neck cancer	0.000141	0.000215	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—head and neck cancer	0.000141	0.000215	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CASP8—head and neck cancer	0.000139	0.000212	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GRP—head and neck cancer	0.000139	0.000212	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—MAPK3—head and neck cancer	0.000138	0.000212	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—AKT1—head and neck cancer	0.000138	0.000212	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	0.000138	0.00021	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	0.000137	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—AKT1—head and neck cancer	0.000137	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—AKT1—head and neck cancer	0.000137	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—AKT1—head and neck cancer	0.000136	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT6—head and neck cancer	0.000135	0.000206	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—AKT1—head and neck cancer	0.000135	0.000206	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—AKT1—head and neck cancer	0.000134	0.000205	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—MAPK1—head and neck cancer	0.000134	0.000205	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—MAPK3—head and neck cancer	0.000134	0.000205	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000134	0.000204	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000133	0.000203	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—head and neck cancer	0.000132	0.000202	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000132	0.000201	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—MAPK1—head and neck cancer	0.000132	0.000201	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—head and neck cancer	0.000132	0.000201	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CASP8—head and neck cancer	0.00013	0.000199	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	0.00013	0.000198	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—AKT1—head and neck cancer	0.00013	0.000198	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	0.000129	0.000197	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—YAP1—head and neck cancer	0.000128	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—MAPK1—head and neck cancer	0.000127	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—head and neck cancer	0.000127	0.000195	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000127	0.000194	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MAPK3—head and neck cancer	0.000125	0.000191	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000125	0.000191	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—PIK3CA—head and neck cancer	0.000124	0.00019	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—PIK3CA—head and neck cancer	0.000122	0.000187	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	0.000121	0.000186	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—YAP1—head and neck cancer	0.000119	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—BCL2—head and neck cancer	0.000119	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MAPK1—head and neck cancer	0.000119	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—head and neck cancer	0.000119	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—PIK3CA—head and neck cancer	0.000116	0.000178	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HRAS—head and neck cancer	0.000115	0.000176	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—PIK3CA—head and neck cancer	0.000114	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—HRAS—head and neck cancer	0.000113	0.000173	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—BCL2—head and neck cancer	0.000112	0.00017	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—UROD—head and neck cancer	0.000112	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HRAS—head and neck cancer	0.000108	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—HRAS—head and neck cancer	0.000106	0.000162	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—HRAS—head and neck cancer	0.000102	0.000156	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—head and neck cancer	0.000101	0.000154	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—STAT3—head and neck cancer	0.0001	0.000153	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—AKT1—head and neck cancer	9.98e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—BCL2L1—head and neck cancer	9.9e-05	0.000151	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PTEN—head and neck cancer	9.88e-05	0.000151	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—HRAS—head and neck cancer	9.57e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MAPK3—head and neck cancer	9.56e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—head and neck cancer	9.45e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—STAT3—head and neck cancer	9.36e-05	0.000143	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—AKT1—head and neck cancer	9.34e-05	0.000143	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BCL2L1—head and neck cancer	9.27e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PTEN—head and neck cancer	9.24e-05	0.000141	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	9.16e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MAPK1—head and neck cancer	9.1e-05	0.000139	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—head and neck cancer	9.09e-05	0.000139	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	9.07e-05	0.000139	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MAPK3—head and neck cancer	8.94e-05	0.000137	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NAT2—head and neck cancer	8.63e-05	0.000132	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MAPK1—head and neck cancer	8.51e-05	0.00013	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—head and neck cancer	8.51e-05	0.00013	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MAPK3—head and neck cancer	8.44e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOTCH1—head and neck cancer	8.21e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CASP8—head and neck cancer	8.1e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MAPK1—head and neck cancer	8.03e-05	0.000123	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—head and neck cancer	8.03e-05	0.000123	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDH1—head and neck cancer	8e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK3—head and neck cancer	7.9e-05	0.000121	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOTCH1—head and neck cancer	7.68e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CASP8—head and neck cancer	7.57e-05	0.000116	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—DPYD—head and neck cancer	7.57e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK1—head and neck cancer	7.52e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—head and neck cancer	7.51e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDH1—head and neck cancer	7.48e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—head and neck cancer	7.3e-05	0.000112	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—YAP1—head and neck cancer	7.18e-05	0.00011	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—head and neck cancer	6.97e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—BCL2—head and neck cancer	6.95e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—head and neck cancer	6.83e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2—head and neck cancer	6.69e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—head and neck cancer	6.52e-05	9.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BCL2—head and neck cancer	6.5e-05	9.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—head and neck cancer	6.45e-05	9.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—head and neck cancer	6.45e-05	9.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—head and neck cancer	6.26e-05	9.57e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—head and neck cancer	6.12e-05	9.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—head and neck cancer	6.09e-05	9.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—head and neck cancer	6.03e-05	9.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—head and neck cancer	6.03e-05	9.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—head and neck cancer	5.76e-05	8.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH1—head and neck cancer	5.75e-05	8.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—head and neck cancer	5.72e-05	8.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—head and neck cancer	5.7e-05	8.71e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—head and neck cancer	5.69e-05	8.7e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	5.39e-05	8.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—head and neck cancer	5.38e-05	8.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK3—head and neck cancer	5.38e-05	8.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH1—head and neck cancer	5.38e-05	8.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—head and neck cancer	5.33e-05	8.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—head and neck cancer	5.31e-05	8.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—head and neck cancer	5.15e-05	7.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK1—head and neck cancer	5.12e-05	7.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—head and neck cancer	5.12e-05	7.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK3—head and neck cancer	5.04e-05	7.69e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—head and neck cancer	4.97e-05	7.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK3—head and neck cancer	4.92e-05	7.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—head and neck cancer	4.82e-05	7.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK1—head and neck cancer	4.79e-05	7.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—head and neck cancer	4.79e-05	7.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—head and neck cancer	4.75e-05	7.26e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	4.7e-05	7.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK1—head and neck cancer	4.68e-05	7.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—head and neck cancer	4.68e-05	7.15e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NAT2—head and neck cancer	4.63e-05	7.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK3—head and neck cancer	4.6e-05	7.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK3—head and neck cancer	4.54e-05	6.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—head and neck cancer	4.45e-05	6.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—head and neck cancer	4.44e-05	6.79e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK1—head and neck cancer	4.38e-05	6.69e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—head and neck cancer	4.38e-05	6.69e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK1—head and neck cancer	4.32e-05	6.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—head and neck cancer	4.32e-05	6.6e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMS—head and neck cancer	4.31e-05	6.59e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—head and neck cancer	4.26e-05	6.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK3—head and neck cancer	4.25e-05	6.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—head and neck cancer	4.16e-05	6.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—head and neck cancer	4.11e-05	6.28e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GPX1—head and neck cancer	4.08e-05	6.23e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—DPYD—head and neck cancer	4.06e-05	6.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—head and neck cancer	4.06e-05	6.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK1—head and neck cancer	4.04e-05	6.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—head and neck cancer	4.04e-05	6.17e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A1—head and neck cancer	4.04e-05	6.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—head and neck cancer	3.95e-05	6.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—head and neck cancer	3.86e-05	5.89e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—YAP1—head and neck cancer	3.85e-05	5.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—head and neck cancer	3.85e-05	5.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—head and neck cancer	3.8e-05	5.8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—head and neck cancer	3.76e-05	5.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—head and neck cancer	3.75e-05	5.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—head and neck cancer	3.72e-05	5.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—head and neck cancer	3.7e-05	5.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—head and neck cancer	3.63e-05	5.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—head and neck cancer	3.61e-05	5.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—head and neck cancer	3.51e-05	5.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—head and neck cancer	3.51e-05	5.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—head and neck cancer	3.48e-05	5.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—head and neck cancer	3.47e-05	5.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—head and neck cancer	3.4e-05	5.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—head and neck cancer	3.36e-05	5.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—head and neck cancer	3.33e-05	5.08e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.32e-05	5.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—head and neck cancer	3.32e-05	5.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—head and neck cancer	3.24e-05	4.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK3—head and neck cancer	3.18e-05	4.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—head and neck cancer	3.14e-05	4.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—neck—head and neck cancer	3.12e-05	0.171	CbGeAlD
Trametinib—MAP2K1—Signaling Pathways—STAT3—head and neck cancer	3.11e-05	4.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—head and neck cancer	3.1e-05	4.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—head and neck cancer	3.06e-05	4.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK1—head and neck cancer	3.03e-05	4.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—head and neck cancer	3.02e-05	4.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK3—head and neck cancer	2.97e-05	4.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—head and neck cancer	2.86e-05	4.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK1—head and neck cancer	2.83e-05	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—head and neck cancer	2.83e-05	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—head and neck cancer	2.62e-05	4.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—head and neck cancer	2.54e-05	3.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—head and neck cancer	2.46e-05	3.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—head and neck cancer	2.43e-05	3.71e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—head and neck cancer	2.4e-05	3.67e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—head and neck cancer	2.38e-05	3.63e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMS—head and neck cancer	2.31e-05	3.53e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—head and neck cancer	2.29e-05	3.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—head and neck cancer	2.27e-05	3.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—connective tissue—head and neck cancer	2.24e-05	0.123	CbGeAlD
Trametinib—CYP3A4—Metabolism—GPX1—head and neck cancer	2.19e-05	3.35e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	2.17e-05	3.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—saliva-secreting gland—head and neck cancer	2.15e-05	0.118	CbGeAlD
Trametinib—MAP2K2—Signaling Pathways—AKT1—head and neck cancer	2.14e-05	3.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—epithelium—head and neck cancer	2.13e-05	0.117	CbGeAlD
Trametinib—CYP2C8—Metabolism—PTEN—head and neck cancer	2.1e-05	3.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—head and neck cancer	2.01e-05	3.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—lymphoid tissue—head and neck cancer	1.64e-05	0.0897	CbGeAlD
Trametinib—CYP2C8—Metabolism—PIK3CA—head and neck cancer	1.48e-05	2.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—lymphoid tissue—head and neck cancer	1.44e-05	0.079	CbGeAlD
Trametinib—MAP2K1—head—head and neck cancer	1.32e-05	0.0723	CbGeAlD
Trametinib—MAP2K2—thyroid gland—head and neck cancer	1.31e-05	0.0718	CbGeAlD
Trametinib—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.29e-05	1.97e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—head and neck cancer	1.21e-05	1.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—head—head and neck cancer	1.16e-05	0.0637	CbGeAlD
Trametinib—CYP3A4—Metabolism—PTEN—head and neck cancer	1.12e-05	1.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—lymph node—head and neck cancer	9.24e-06	0.0506	CbGeAlD
Trametinib—MAP2K2—lymph node—head and neck cancer	8.13e-06	0.0446	CbGeAlD
Trametinib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	7.93e-06	1.21e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—head and neck cancer	6.48e-06	9.9e-06	CbGpPWpGaD
